RG7795: Difference between revisions
Content deleted Content added
link typo |
m Normalize {{Multiple issues}}: Remove {{Multiple issues}} for only 1 maintenance template(s): Notability |
||
| Line 1: | Line 1: | ||
{{Multiple issues| |
|||
{{Orphan|date=December 2011}} |
{{Orphan|date=December 2011}} |
||
{{notability|date=March 2015}} |
{{notability|date=March 2015}} |
||
}} |
|||
{{Drugbox |
{{Drugbox |
||
Revision as of 11:16, 31 May 2020
 | The topic of this article may not meet Wikipedia's general notability guideline. (March 2015) |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.[1] It is an orally-available prodrug of isatoribine,[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.[3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.[2]
References
- ^ "RG 7795". AdisInsight. Retrieved 28 August 2017.
- ^ a b Funk, E; Kottilil, S; Gilliam, B; Talwani, R (14 May 2014). "Tickling the TLR7 to cure viral hepatitis". Journal of Translational Medicine. 12: 129. doi:10.1186/1479-5876-12-129. PMC 4039542. PMID 24884741.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, 2016.